Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Sangamo Therapeutics (SGMO) Shares Outstanding (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Shares Outstanding for 16 consecutive years, with $350.7 million as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 64.77% year-over-year to $350.7 million; the TTM value through Dec 2025 reached $350.7 million, up 64.77%, while the annual FY2025 figure was $350.7 million, 64.77% up from the prior year.
  • Shares Outstanding hit $350.7 million in Q4 2025 for Sangamo Therapeutics, up from $322.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $350.7 million in Q4 2025 and bottomed at $143.7 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $195.9 million, with a median of $177.2 million recorded in 2023.
  • Year-over-year, Shares Outstanding grew 2.05% in 2022 and then soared 64.77% in 2025.
  • Sangamo Therapeutics' Shares Outstanding stood at $145.9 million in 2021, then grew by 14.3% to $166.8 million in 2022, then grew by 6.8% to $178.1 million in 2023, then grew by 19.48% to $212.8 million in 2024, then skyrocketed by 64.77% to $350.7 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $350.7 million, $322.0 million, and $272.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.